{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:36Z","timestamp":1792786116514,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"European Union\u2019s Horizon 2020","award":["779295"],"award-info":[{"award-number":["779295"]}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institute Strategic Program Grant","award":["BBS\/E\/B\/000C0427"],"award-info":[{"award-number":["BBS\/E\/B\/000C0427"]}]},{"name":"Institute Strategic Program Grant","award":["BBS\/E\/B\/000C0428"],"award-info":[{"award-number":["BBS\/E\/B\/000C0428"]}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["1S22716N"],"award-info":[{"award-number":["1S22716N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In 2016 specific heterozygous gain-of-function mutations in the Mediterranean fever gene MEFV were reported as causal for a distinct autoinflammatory disease coined pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND). We sought to provide an extended report on clinical manifestations in PAAND patients to date and evaluate the efficacy and safety of treatment with the IL-1-blocking agent anakinra.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We undertook an open-label pilot study with anakinra. Three patients were recruited in a preliminary phase of the study with the intention to expand the treatment cohort in case of a favourable response. Acute-phase reactants and plasma cytokine levels were monitored throughout. Skin biopsies at baseline and at week 12 were stained for relevant cytokines. Available clinical data on treatment responses were retrospectively collected on additional patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The three patients from the preliminary phase of the study [patients 1\u20133 (P1\u2013P3)] demonstrated one failed and two partial treatment responses, where one patient opted to continue treatment with anakinra and the other favoured adalimumab. While a partial systemic response was observed, there was no appreciable effect of anakinra on the prominent cutaneous manifestations, reflected in residual local inflammatory cytokine expression in lesional skin. These observations did not warrant further expansion of the treatment cohort. Clinical data was retrospectively collected on an additional eight patients (P4\u2013P11), highlighting both dominant and recessive inheritance with variable penetrance in PAAND and common gastrointestinal involvement that was not previously appreciated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our experience, while anakinra appears safe, it was not superior to biologicals targeting TNF-\u03b1 in PAAND despite evidence directly implicating dysregulated IL-1\u03b2 signalling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab221","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T15:12:45Z","timestamp":1614870765000},"page":"5436-5446","source":"Crossref","is-referenced-by-count":17,"title":["Phenotypic analysis of pyrin-associated autoinflammation with neutrophilic dermatosis patients during treatment"],"prefix":"10.1093","volume":"60","author":[{"given":"Erika","family":"Van Nieuwenhove","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven"},{"name":"VIB Center for Brain and Disease Research"},{"name":"Department of Pediatrics, University Hospitals Leuven"},{"name":"Member European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases \u2013 Project ID No 739543"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-2146","authenticated-orcid":false,"given":"Ellen","family":"De Langhe","sequence":"additional","affiliation":[{"name":"Member European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases \u2013 Project ID No 739543"},{"name":"Department of Development and Regeneration, Laboratory of Tissue Homeostasis and Disease, KU Leuven"},{"name":"Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Dooley","sequence":"additional","affiliation":[{"name":"Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, Babraham Research Campus, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Van Den Oord","sequence":"additional","affiliation":[{"name":"Department of Pathology, UZ Leuven, Laboratory of Translational Cell and Tissue Research, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shahrooei","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven"},{"name":"Specialized Immunology Laboratory of Dr Shahrooei, Ahvaz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Parvaneh","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Pediatrics, Tehran University of Medical Sciences"},{"name":"Research Center for Immunodeficiencies, Tehran University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4648-3573","authenticated-orcid":false,"given":"Vahid","family":"Ziaee","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Research Group, Rheumatology Research Center, Tehran University of Medical Sciences"},{"name":"Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7910-0554","authenticated-orcid":false,"given":"Sinisa","family":"Savic","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kacar","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Humblet-Baron","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven"},{"name":"VIB Center for Brain and Disease Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Liston","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven"},{"name":"VIB Center for Brain and Disease Research"},{"name":"Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Wouters","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven"},{"name":"Department of Pediatrics, University Hospitals Leuven"},{"name":"Member European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases \u2013 Project ID No 739543"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"2021110402581289100_keab221-B1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","article-title":"Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes","volume":"97","author":"McDermott","year":"1999","journal-title":"Cell"},{"key":"2021110402581289100_keab221-B2","doi-asserted-by":"crossref","first-page":"332ra45","DOI":"10.1126\/scitranslmed.aaf1471","article-title":"Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation","volume":"8","author":"Masters","year":"2016","journal-title":"Sci Transl Med"},{"key":"2021110402581289100_keab221-B3","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/annrheumdis-2017-211473","article-title":"A novel pyrin-associated autoinflammation with neutrophilic dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever","volume":"76","author":"Moghaddas","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021110402581289100_keab221-B4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature13449","article-title":"Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome","volume":"513","author":"Xu","year":"2014","journal-title":"Nature"},{"key":"2021110402581289100_keab221-B5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00296-011-2096-3","article-title":"Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations","volume":"32","author":"Kaiser","year":"2012","journal-title":"Rheumatol Int"},{"key":"2021110402581289100_keab221-B6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2018-214102","article-title":"Autoinflammation due to homozygous S208 MEFV mutation","volume":"78","author":"Hong","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021110402581289100_keab221-B7","first-page":"756","article-title":"Short-term efficacy of adalimumab in a patient with pyrin-associated autoinflammation with neutrophilic dermatosis","volume":"16","author":"Gargallo","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"2021110402581289100_keab221-B8","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1186\/ar4154","article-title":"High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first- degree relatives: further evidence for the connection","volume":"15","author":"Akar","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2021110402581289100_keab221-B9","first-page":"S160","article-title":"Are MEFV mutations susceptibility factors in enthesitis-related arthritis patients in the eastern Mediterranean?","volume":"32","author":"G\u00fclhan","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2021110402581289100_keab221-B10","first-page":"doi","article-title":"Evaluation of familial Mediterranean fever patients concomitant with juvenile spondyloarthropathy","author":"K\u0131saarslan","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2021110402581289100_keab221-B11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/ijd.13603","article-title":"Autoinflammatory syndromes associated with hidradenitis suppurativa and\/or acne","volume":"56","author":"Vinkel","year":"2017","journal-title":"Int J Dermatol"},{"key":"2021110402581289100_keab221-B12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3389\/fimmu.2019.01059","article-title":"Mechanisms of inflammation in neutrophil-mediated skin diseases","volume":"10","author":"Marzano","year":"2019","journal-title":"Front Immunol"},{"key":"2021110402581289100_keab221-B13","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/bjd.15226","article-title":"Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis","volume":"176","author":"Marzano","year":"2017","journal-title":"Br J Dermatol"},{"key":"2021110402581289100_keab221-B14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjd.14691","article-title":"Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation","volume":"175","author":"Marzano","year":"2016","journal-title":"Br J Dermatol"},{"key":"2021110402581289100_keab221-B15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-017-0265-1","article-title":"PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment","volume":"18","author":"Cugno","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2021110402581289100_keab221-B16","doi-asserted-by":"crossref","first-page":"E4857","DOI":"10.1073\/pnas.1601700113","article-title":"Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation","volume":"113","author":"Gao","year":"2016","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab221\/36973298\/keab221.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5436\/41073366\/keab221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5436\/41073366\/keab221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T23:01:57Z","timestamp":1635980517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/11\/5436\/6162885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,3,8]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab221","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,3,8]]}}}